Harbor Capital Advisors Inc. Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Harbor Capital Advisors Inc. raised its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 57.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,105 shares of the company’s stock after purchasing an additional 6,612 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Tarsus Pharmaceuticals were worth $595,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TARS. Quest Partners LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at about $61,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after purchasing an additional 1,530 shares during the last quarter. Dark Forest Capital Management LP acquired a new position in Tarsus Pharmaceuticals in the second quarter worth $202,000. Finally, Bleakley Financial Group LLC bought a new stake in Tarsus Pharmaceuticals during the first quarter valued at $223,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TARS. Oppenheimer restated an “outperform” rating and issued a $63.00 price target (up from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $51.60.

Tarsus Pharmaceuticals Trading Up 2.5 %

Tarsus Pharmaceuticals stock opened at $46.80 on Thursday. The firm has a 50-day moving average price of $34.71 and a two-hundred day moving average price of $31.69. Tarsus Pharmaceuticals, Inc. has a 52-week low of $15.47 and a 52-week high of $51.59. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -10.45 and a beta of 1.00. The company has a quick ratio of 6.99, a current ratio of 7.03 and a debt-to-equity ratio of 0.28.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The firm had revenue of $40.81 million for the quarter, compared to analysts’ expectations of $31.30 million. During the same period last year, the firm earned ($1.17) EPS. Sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.71 earnings per share for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.